GSK Wins FDA Nod for Novel Hepatitis B Drug Offering a Potential Functional Cure

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 21 Oct, 18:38 UTC

GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to make copies of itself and viral proteins. This drug was licensed from antisense oligonucleotide specialist Ionis Pharmaceuticals. The post GSK Wins FDA Nod for Novel Hepatitis…

science

Sources

• T2GSK Wins FDA Nod for Novel Hepatitis B Drug Offering a Potential Functional CureFierce Biotech / Fierce Healthcare / MedCity / GEN21 Oct, 18:38